Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds


The chemistry group is focusing on the design and synthesis of novel multimodal contrast agent conjugates for targeted tumor detection. Applying synthetic organic chemistry, we aim to combine the contrast agent properties for different imaging modalities (MRI, CT, PET, OI, PAI) in one molecule. Additionally, a ligand as well as a therapeutic component will generate a targeted multimodal theranostic agent. With such conjugates we want to gain morphological and functional information of tumors and metastases by means of non-invasive imaging methods. This concept will contribute to the further development of personalized medicine.

Multimodal imaging


We are combining the capabilities of multiple imaging modalities to deliver complementary imaging information for medical and biological research.


  • Magnetic resonance imaging (MRI)
  • Computed tomography (CT)
  • Ultrasound/photoacoustic imaging (PAI): Photoacoustic imaging is a hybrid imaging modality based on the irradiation of the tissue of interest with pulsed (nanosecond) lasers, and consequent acquisition of pressure waves generated using an ultrasonic transducer array.

Biological and computational imaging:

  • Quantification of tumor growth and proliferation using MRI, US and fluorescence/bioluminescence imaging.
  • Quantitative study of the microvasculature in preclinical tumor models and characterization of the tumor perfusion profiles using dynamic contrast enhanced MRI, non-linear contrast ultrasound and real-time photoacoustic measurement.
  • Characterization of oxygen saturation profiles and identification of neovascularization using multispectral photoacoustic imaging.
  • Computational image analysis of the in vivo imaging data, and the use of cross-modality visual information for image quality enhancement.
  • Validation of imaging results - correlation with histology/immunohistochemistry.

to top
powered by webEdition CMS